Fibrin rich in leukocytes and platelets (L-PRF) and bisphosphonate-induced osteonecrosis: we need to advertise now

• Autor(a) principal: Faria, Maria de Fátima
• Data de Publicação: 2019
• Outros Autores: Cabral, Eric Lucas dos Santos, Castro, Wilkson Ricardo Silva, Florentino, Davidson Rogério de Medeiros, Costa Junior, João Florêncio da, Souza, Ricardo Pires de, Guzen, Fausto Pierdoná, Pinheiro, Francisco Irochima, Rêgo, Amália Cinthia Meneses, Araújo Filho, Irami
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRN
• Texto Completo: https://repositorio.ufrn.br/handle/123456789/33257
• topic: Leukocyte and platelet-rich fibrin; L-PRF; Platelet-rich fibrin; Bisphosphonate-associated osteonecrosis of the jaw,; Bisphosphonate-associated osteonecrosis; Bisphosphonate related osteonecrosis of the jaw

The American Association of Oral and Maxillofacial Surgeons (AAOMS) reported in 2004 a new pathology that causes osteonecrosis in the Maxillomandibular complex. The condition was named Bisphosphonate-related osteonecrosis of the jaw (BRONJ), and later renamed by medication related to jaw osteonecrosis due to the appearance of severe alveolar bone loss in the Maxillomandibular complex resulting from the use of different drugs other than Bisphosphonates. Odontology, especially oral surgery, a field concerned with newbiotechnologies, has been introducing innovations in tissue engineering. Oro-maxillofacial reconstruction is of great interest to current oral and maxillofacial surgeons, as part of the search for strategies in bioengineering and biomaterials, a major promoter of bio-dental research in our times. In order to verify the scientific evidences to analyse the effectiveness of leukocyte and platelet rich fibrin (L-PRF) on bone neoformation inMaxillomandibular complex’s surgical procedures, a search for qualified articles was conducted in the Medline (PubMed), Embase and Cochrane Central Register of Controlled Trials databases. The works analysed were published from 2013 to 2018. This review concludes that the use of platelet rich fibrin (L-PRF) is significant in the complete healing of the lesion in short postoperative periods and in the resolution of the treatments, reducing the need for postoperative re-interventions, resulting in lower morbidity for the patients